Współistnienie cukrzycy typu 2 oraz przewlekłej niewydolności serca – nieprzypadkowe skojarzenie Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Roman Załuska
Marcin Grabowski

Abstrakt

W ostatnich latach u coraz większej liczby pacjentów dochodzi do współistnienia cukrzycy typu 2 z przewlekłą niewydolnością serca. Ma to bardzo niekorzystny wpływ na rokowanie i wymaga rozważnego planowania terapii uwzględniającego stan danego pacjenta, w tym obecność innych schorzeń. Szczególną uwagę należy zwrócić na obecność przewlekłej choroby nerek, która wpływa na dawkowanie i działanie wielu preparatów. Ważnym aspektem stosowanej terapii jest podwyższone ryzyko hipoglikemii. Trzeba także pamiętać, że cele terapii w tej grupie są nieco inne niż w populacji ogólnej. W zaleceniach ESC w terapii cukrzycy typu 2 u osób z podwyższonym ryzykiem rozwoju niewydolności serca na pierwszy plan wysuwa się nowa grupa leków hipoglikemizujących inhibitory SGLT-2 (empagliflozyna, kanagliflozyna, dapagliflozyna), które zmniejszają częstość hospitalizacji z powodu niewydolności serca o 32–35%. U pacjentów z już istniejącą niewydolnością i cukrzycą metody leczenia nie różnią się od stosowanych w populacji bez cukrzycy typu 2.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Załuska , R., & Grabowski , M. (2020). Współistnienie cukrzycy typu 2 oraz przewlekłej niewydolności serca – nieprzypadkowe skojarzenie. Kardiologia W Praktyce, 14(1-2), 45-51. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1175
Dział
Medycyna metaboliczna

Bibliografia

1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017; 3(1): 7-11. http://doi.org/10.15420/cfr.2016:25:2.
2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators [published correction appears in Lancet. 2017; 389: e1]. Lancet. 2016; 388(10053): 1545-602. http://doi.org/10.1016/S0140-6736(16)31678-6.
3. From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006; 119(7): 591-9. http://doi.org/ 10.1016/j.amjmed.2006.05.024.
4. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996; 77(11): 1017-20.
5. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe, part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 249(5): 442-63.
6. Dei Cas A, Fonarow GC, Gheorghiade M et al. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol. 2015; 40(1): 7-43. http://doi.org/10.1016/j.cpcardiol.2014.09.002.
7. Sandesara PB, O’Neal WT, Kelli HM et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care. 2018; 41: 150-5. http://doi.org/10.2337/dc17-0755.
8. Nichols GA, Gullion CM, Koro CE et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27(8): 1879-84.
9. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004; 27(3): 699-703.
10. Boonman-de Winter LJ, Rutten FH, Cramer MJ et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55(8): 2154-62. http://doi.org/10.1007/s00125-012-2579-0.
11. Thrainsdottir IS, Aspelund T, Thorgeirsson G et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005; 28(3): 612-6.
12. van Melle JP, Bot M, de Jonge P et al. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the Heart and Soul Study. Diabetes Care. 2010; 33(9): 2084-9. http://doi.org/10.2337/dc10-0286.
13. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103(22): 2668-73.
14. Pazin-Filho A, Kottgen A, Bertoni AG et al. HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008; 51(12): 2197-204. http://doi.org/10.1007/s00125-008-1164-z.
15. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405-12.
16. Bibbins-Domingo K, Lin F, Vittinghoff E et al. Predictors of heart failure among women with coronary disease. Circulation. 2004; 110: 1424-30. http://doi.org/10.1161/01.CIR. 0000141726.01302.83.
17. Scirica BM, Braunwald E, Raz I et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation. 2015;132:e198]. Circulation. 2014; 130(18): 1579-88. http://doi.org/10.1161/CIRCULATIONAHA.114.010389.
18. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000; 101(19): 2271-6.
19. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006; 48(8): 1548-51. http://doi.org/10.1016/j.jacc.2006.07.033.
20. Palmieri V, Bella JN, Arnett DK et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001; 103(1): 102-7.
21. Rutter MK, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003; 107(3): 448-54.
22. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study [published correction appears in J Am Coll Cardiol. 2010; 56: 1612]. J Am Coll Cardiol. 2010; 55(4): 300-5. http://doi.org/10.1016/j.jacc.2009.12.003.
23. Swoboda PP, McDiarmid AK, Erhayiem B et al. Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc. 2017; 6(7): e005539. http://doi.org/10.1161/JAHA.117.005539.
24. Wang TJ, Evans JC, Benjamin EJ et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8): 977-82. http://doi.org/10.1161/01.CIR.0000085166.44904.79.
25. Wang TJ, Levy D, Benjamin EJ et al. The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med. 2003; 138(11): 907-16.
26. Paolillo S, Rengo G, Pellegrino T et al. Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. 2015; 16(10): 1148-53. http://doi.org/10.1093/ehjci/jev061.
27. Fang ZY, Yuda S, Anderson V et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003; 41(4): 611-17.
28. Dunlay SM, Redfield MM, Weston SA et al. Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol. 2009; 54(18): 1695-702. http://doi.org/10.1016/j.jacc.2009.08.019.
29. Chaudhry SI, McAvay G, Chen S et al. Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. J Am Coll Cardiol. 2013; 61(6): 635-42. http://doi.org/10.1016/j.jacc.2012.11.027.
30. Lawson CA, Jones PW, Teece L et al. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. JACC Heart Fail. 2018; 6(1): 18-26. http://doi.org/10.1016/j.jchf.2017.08.020.
31. Castagno D, Baird-Gunning J, Jhund PS et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011; 162(5): 938-48.e2. http://doi.org/10.1016/j.ahj.2011.07.030.
32. Elder DH, Singh JS, Levin D et al. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2016; 18(1): 94-102. http://doi.org/10.1002/ejhf.455.
33. Selvin E, Rawlings AM, Lutsey PL et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation. 2015; 132(4): 269-77. http://doi.org/10.1161/CIRCULATIONAHA.115.015415.
34. Aguilar D, Bozkurt B, Ramasubbu K et al. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009; 54(5): 422-8. http://doi.org/10.1016/j.jacc.2009.04.049.
35. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006; 151(1): 91. http://doi.org/10.1016/j.ahj.2005.10.008.
36. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-28.
37. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018; 137(4): 323-34.
38. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347-57.
39. Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003; 107(9): 1291-6.
40. Yusuf S, Ostergren JB, Gerstein HC et al. on behalf of the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure [published correction appears in Circulation. 2005; 112: e292]. Circulation. 2005; 112(1): 48-53. http://doi.org/10.1161/CIRCULATIONAHA.104.528166.
41. Seferovic JP, Claggett B, Seidelmann SB et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5(5): 333-40. http://doi.org/10.1016/S2213-8587(17)30087-6.
42. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strategies. 2012; 9(4): e131-e9.
43. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J. 2010; 160(5): 915-21. http://doi.org/10.1016/j.ahj.2010.04.024.
44. Ferrua S, Bobbio M, Catalano E et al. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail. 2005; 11(8): 590-4. http://doi.org/10.1016/j.cardfail.2005.06.431.
45. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010; 26(3): 615-29. http://doi.org/10.1185/03007990903533681.
46. Wai B, Kearney LG, Hare DL et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012; 11: 14. http://doi.org/10.1186/1475-2840-11-14.
47. Torp-Pedersen C, Metra M, Charlesworth A et al. COMET Investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007; 93(8): 968-73. http://doi.org/10.1136/hrt.2006.092379.
48. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577-89. http://doi.org/10.1056/NEJMoa0806470.
49. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72. http://doi.org/10.1056/NEJMoa0802987.
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999; 354 (9178): 602]. Lancet. 1998; 352(9131): 837-53.
51. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998; 352(9139): 1558]. Lancet. 1998; 352(9131): 854-65.
52. Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016; 9(5): 504-12. http://doi.org/10.1161/CIRCOUTCOMES.116.002901.
53. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545-59. http://doi.org/10.1056/NEJMoa0802743.
54. Hayward RA, Reaven PD, Wiitala WL et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes [published correction appears in N Engl J Med. 2015;373:198]. N Engl J Med. 2015; 372(23): 2197-206. http://doi.org/10.1056/NEJMoa1414266.
55. Holman RR, Bethel MA, Mentz RJ et al. Effects of once‑weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228-39.
56. Marso SP, Daniels GH, Brown‑Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311-22.
57. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247-57.
58. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834-44.
59. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381(9): 841-51. http://doi.org/10.1056/ NEJMoa1901118.
60. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial. Lancet. 2019; 394(10193): 121-30.
61. Jorsal A, Kistorp C, Holmager P et al. Effect of liraglutide, a glucagon‑like peptide‑1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo‑controlled trial. Eur J Heart Fail. 2017; 19: 69-77.
62. Margulies KB, Hernandez AF, Redfield MM et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016; 316(5): 500-8.
63. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-42.
64. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321(1): 69-79.
65. Smooke S, Horwich TB, Fonarow GC. Insulin‑treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005; 149(1): 168-74.
66. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279-89.
67. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096-105.
68. Hernandez AV, Usmani A, Rajamanickam A et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta‑analysis and meta‑regression analysis of placebo‑controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011; 11(2): 115-28.
69. Home PD, Pocock SJ, Beck‑Nielsen H et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RE‑CORD): a multicentre, randomised, open‑label trial. Lancet. 2009; 373(9681): 2125-35.